Bladder Cancer Weekly

April 06, 2026

Videos

Peer-to-Peer Clinical Conversations

Cystoscopy vs Urinary Markers: A Debate on Bladder Cancer Surveillance Strategies - Jeremy Teoh & Laura Mertens

Ashish Kamat moderates a debate between Jeremy Teoh and Laura Mertens on cystoscopy versus urinary markers for NMIBC surveillance.

View

Patient-Reported Outcomes and Qualitative Insights Inform Shared Decision-Making for Mitomycin Intravesical Solution - Ruchika Talwar

Ruchika Talwar discusses data on patient-reported outcomes with mitomycin intravesical solution (ZUSDURI™) in recurrent low-grade intermediate-risk NMIBC.

View

Beyond the Abstracts

Optimizing Oncological Outcomes in High-Grade Non-Muscle Invasive Bladder Cancer: The Impact of a Surgeon-Led Treatment Pathway - Beyond the Abstract

Prognostic Factors of Trimodal Therapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis - Beyond the Abstract

Conference Coverage

SES AUA 2026: Differences in Restaging TURBT Pathology Outcomes Based on Index TURBT Performed by an SUO Fellowship Trained or Non-SUO Trained Urologist  

EAU 2026: Treatment of High-grade NMIBC: Results from the VERSUS Study

EAU 2026: Case-Based Panel Discussion Beyond Platinum: Evolving Frontlines in mUC: Where Do ADCs Fit in the Sequencing?

ASCO GU 2026: Circulating Tumor DNA Analysis from the Prospective pT0 Study of Systematic Endoscopic Evaluation in Patients Undergoing Radical Cystectomy for Bladder Cancer

ASCO GU 2026: Treatment Patterns and Outcomes with Second-line Therapies in Patients with Advanced Urothelial Carcinoma Previously Treated with First-line Enfortumab Vedotin with Pembrolizumab

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Costs of care and oncologic outcomes associated with blue light cystoscopy in an equal access setting: Results from the BRAVO study.

Impact of a multidisciplinary approach on outcomes in urothelial carcinoma.

Real-World Survival Outcomes and Prognostic Factors in De Novo Stage IV Urothelial Bladder Cancer: A 13-Year Retrospective Cohort Study.

INLEXZO™ (gemcitabine intravesical system) Assigned Permanent Billing Code, Supporting Access for Patients with Certain Bladder Cancers

NCCN 2026 Bladder Cancer Guidelines Adopt IBCG Risk Stratification Model for Intermediate-Risk NMIBC

Active surveillance in low-grade NMIBC - results of an international two-round modified Delphi consensus.

Impact of audit and feedback on transurethral resection of bladder tumour quality: a monocentric post-completion evaluation of the RESECT trial.

Recent advances in immunotherapy for bladder cancer: mechanisms, clinical applications, and future perspectives.

Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab.

AI-assessed sarcopenia as an independent predictor of neoadjuvant chemotherapy outcomes in muscle-invasive bladder cancer.

Cost-Effectiveness of Perioperative Durvalumab With Neoadjuvant Gemcitabine/Cisplatin in Muscle-Invasive Bladder Cancer Treatment.

ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026

Is complete TURBT mandatory before radical cystectomy in cases of muscle-invasive bladder cancer?

Assessing Treatment Outcomes of Patients Undergoing Enfortumab Vedotin Dose Reduction in Metastatic Bladder Cancer.

Cost-Effectiveness of Circulating Tumor DNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer Based on IMvigor011 Trial.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Bladder Cancer Weekly

Bladder Cancer

Login